Publications - The Institute of Cancer Research, London

Publications Highlights View all by category

Types of Publications

Journals
Conference

Journal Articles

Zeidan, A.M. Boss, I.W. Beach, C.L. Copeland, W.B. Thompson, E.G. Fox, B.A. Hasle, V.E. Hellmann, A. Taussig, D. Tormo, M. Voso, M.T. Cavenagh, J. O'Connor, T. Previtali, A. Rose, S. Silverman, L.R. (2021). Azacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia. Blood advances, . show abstract

Moore, A.S. Faisal, A. Mak, G.W. Miraki-Moud, F. Bavetsias, V. Valenti, M. Box, G. Hallsworth, A. de Haven Brandon, A. Xavier, C.P. Stronge, R. Pearson, A.D. Blagg, J. Raynaud, F.I. Chopra, R. Eccles, S.A. Taussig, D.C. Linardopoulos, S. (2020). Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. Blood advances, Vol.4 (7), pp. 1478-1491. show abstract

Ghazaly, E.A. Miraki-Moud, F. Smith, P. Gnanaranjan, C. Koniali, L. Oke, A. Saied, M.H. Petty, R. Matthews, J. Stronge, R. Joel, S.P. Young, B.D. Gribben, J. Taussig, D.C. (2020). Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. The journal of biological chemistry, Vol.295 (16), pp. 5496-5508. show abstract

Rio-Machin, A. Vulliamy, T. Hug, N. Walne, A. Tawana, K. Cardoso, S. Ellison, A. Pontikos, N. Wang, J. Tummala, H. Al Seraihi, A.F. Alnajar, J. Bewicke-Copley, F. Armes, H. Barnett, M. Bloor, A. Bödör, C. Bowen, D. Fenaux, P. Green, A. Hallahan, A. Hjorth-Hansen, H. Hossain, U. Killick, S. Lawson, S. Layton, M. Male, A.M. Marsh, J. Mehta, P. Mous, R. Nomdedéu, J.F. Owen, C. Pavlu, J. Payne, E.M. Protheroe, R.E. Preudhomme, C. Pujol-Moix, N. Renneville, A. Russell, N. Saggar, A. Sciuccati, G. Taussig, D. Toze, C.L. Uyttebroeck, A. Vandenberghe, P. Schlegelberger, B. Ripperger, T. Steinemann, D. Wu, J. Mason, J. Page, P. Akiki, S. Reay, K. Cavenagh, J.D. Plagnol, V. Caceres, J.F. Fitzgibbon, J. Dokal, I. (2020). The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nature communications, Vol.11 (1). show abstract

Dillon, R. Hills, R. Freeman, S. Potter, N. Jovanovic, J. Ivey, A. Kanda, A.S. Runglall, M. Foot, N. Valganon, M. Khwaja, A. Cavenagh, J. Smith, M. Ommen, H.B. Overgaard, U.M. Dennis, M. Knapper, S. Kaur, H. Taussig, D. Mehta, P. Raj, K. Novitzky-Basso, I. Nikolousis, E. Danby, R. Krishnamurthy, P. Hill, K. Finnegan, D. Alimam, S. Hurst, E. Johnson, P. Khan, A. Salim, R. Craddock, C. Spearing, R. Gilkes, A. Gale, R. Burnett, A. Russell, N.H. Grimwade, D. (2020). Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood, Vol.135 (9), pp. 680-688. show abstract

Potter, N. Miraki-Moud, F. Ermini, L. Titley, I. Vijayaraghavan, G. Papaemmanuil, E. Campbell, P. Gribben, J. Taussig, D. Greaves, M. (2019). Single cell analysis of clonal architecture in acute myeloid leukaemia. Leukemia, Vol.33 (5), pp. 1113-1123. show abstract

Davies, J.K. Hassan, S. Sarker, S.-. Besley, C. Oakervee, H. Smith, M. Taussig, D. Gribben, J.G. Cavenagh, J.D. (2018). Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia. British journal of haematology, Vol.180 (3), pp. 346-355.

Morilla, R. Moss, K. Nikolova, V. Marquardt, K. Duke, S. Adamowska, K. Fuller, L. Taifoor, A. Johnson, N. Zeisig, A. Morilla, A. Atra, A. Taussig, D.C. (2018). The use of unfixed bone marrow trephines for multicolour flow cytometry. Methods (san diego, calif.), Vol.134-135, pp. 80-86. show abstract

Griessinger, E. Vargaftig, J. Horswell, S. Taussig, D.C. Gribben, J. Bonnet, D. (2018). Acute myeloid leukemia xenograft success prediction: Saving time. Experimental hematology, Vol.59, pp. 66-71.e4. show abstract

Berthon, C. Raffoux, E. Thomas, X. Vey, N. Gomez-Roca, C. Yee, K. Taussig, D.C. Rezai, K. Roumier, C. Herait, P. Kahatt, C. Quesnel, B. Michallet, M. Recher, C. Lokiec, F. Preudhomme, C. Dombret, H. (2016). Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet haematol, Vol.3 (4), pp. e186-e195. show abstract

BACKGROUND: Bromodomain and extraterminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with super-enhancers, including oncogenes. BET proteins bind acetylated histone tails via their bromodomain, bringing the elongation complex to the promoter region. OTX015 (MK-8628) specifically binds to BRD2, BRD3, and BRD4, preventing BET proteins from binding to the chromatin, thus inhibiting gene transcription. OTX015 inhibits proliferation in many haematological malignancy cell lines and patient cells, in vitro and in vivo. We aimed to establish the recommended dose of OTX015 in patients with haematological malignancies. We report the results of patients with acute leukaemia (leukaemia cohort). METHODS: In this dose-escalation, phase 1 study we recruited patients from seven university hospital centres (in France [five], UK [one], and Canada [one]). Adults with acute leukaemia who had failed or had a contraindication to standard therapies were eligible to participate. OTX015 was given orally at increasing doses from 10 mg/day to 160 mg/day (14 of 21 days), using a conventional 3 + 3 design. In this open-label trial, OTX015 was initially administered once a day, with allowance for exploration of other schedules. The primary endpoint was dose-limiting toxicity (DLT), assessed during the first treatment cycle (21 days). The study is ongoing and is registered with ClinicalTrials.gov, NCT01713582. FINDINGS: Between Jan 18, 2013, and Sept 9, 2014, 41 patients, 36 with acute myeloid leukaemia, a median age of 70 years (IQR 60-75) and two lines of previous therapy, were recruited and treated across six dose levels of OTX015. No DLT was recorded until 160 mg/day, when one patient had grade 3 diarrhoea and another had grade 3 fatigue. However, concomitant grade 1-2 non-DLT toxic effects (ie, gastrointestinal, fatigue, or cutaneous) from 120 mg doses hampered patient compliance and 80 mg once a day was judged the recommended dose with a 14 days on, 7 days off schedule. Common toxic effects for all OTX015 doses were fatigue (including grade 3 in three patients) and bilirubin concentration increases (including grade 3-4 in two patients). OTX015 plasma exposure increased proportionally up to 120 mg/day with trough concentrations in the in-vitro active range from 80 mg/day (274 nmol/L). Three patients (receiving 40 mg/day, 80 mg/day, and 160 mg/day) achieved complete remission or complete remission with incomplete recovery of platelets lasting 2-5 months, and two additional patients had partial blast clearance. No predictive biomarkers for response have been identified so far. INTERPRETATION: The once-daily recommended dose for oral, single agent oral OTX015 use in patients with acute leukaemia for further phase 2 studies is 80 mg on a 14 days on, 7 days off schedule. FUNDING: Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp..

Iyengar, S. Ariza‐McNaughton, L. Clear, A. Taussig, D. Auer, R. Roe, A. Lillington, D. Iqbal, S. Joel, S. Gribben, J. Bonnet, D. (2016). Characteristics of human primary mantle cell lymphoma engraftment in NSG mice. British journal of haematology, Vol.173 (1), pp. 165-169.

Griessinger, E. Anjos-Afonso, F. Vargaftig, J. Taussig, D.C. Lassailly, F. Prebet, T. Imbert, V. Nebout, M. Vey, N. Chabannon, C. Filby, A. Bollet-Quivogne, F. Gribben, J.G. Peyron, J.-. Bonnet, D. (2016). Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. Cancer research, Vol.76 (8), pp. 2082-2086. show abstract

Sud, A. Morilla, R. Ethell, M. Taussig, D. Liapis, K. (2015). Green-grey crystals in acute myeloid leukaemia. British journal of haematology, Vol.168 (5), pp. 618-618.

Miraki-Moud, F. Ghazaly, E. Ariza-McNaughton, L. Hodby, K.A. Clear, A. Anjos-Afonso, F. Liapis, K. Grantham, M. Sohrabi, F. Cavenagh, J. Bomalaski, J.S. Gribben, J.G. Szlosarek, P.W. Bonnet, D. Taussig, D.C. (2015). Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood, Vol.125 (26), pp. 4060-4068. show abstract

Griessinger, E. Anjos-Afonso, F. Pizzitola, I. Rouault-Pierre, K. Vargaftig, J. Taussig, D. Gribben, J. Lassailly, F. Bonnet, D. (2014). A Niche-Like Culture System Allowing the Maintenance of Primary Human Acute Myeloid Leukemia-Initiating Cells: A New Tool to Decipher Their Chemoresistance and Self-Renewal Mechanisms. Stem cells translational medicine, Vol.3 (4), pp. 520-529. show abstract

Liapis, K. Taussig, D. Cotter, F.E. Gribben, J.G. (2014). Cutaneous cryptococcosis in Hodgkin lymphoma. British journal of haematology, Vol.164 (4), pp. 467-467.

Liapis, K. Chung, Y. Akhtar, W. Taussig, D. (2014). A patient with rheumatoid arthritis, cryoglobulinaemia, and an "accidental" finding. Bmj, Vol.348 (apr14 3), pp. g2701-g2701.

Manodoro, F. Marzec, J. Chaplin, T. Miraki-Moud, F. Moravcsik, E. Jovanovic, J.V. Wang, J. Iqbal, S. Taussig, D. Grimwade, D. Gribben, J.G. Young, B.D. Debernardi, S. (2014). Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood, Vol.123 (13), pp. 2066-2074. show abstract

Anjos-Afonso, F. Currie, E. Palmer, H.G. Foster, K.E. Taussig, D.C. Bonnet, D. (2013). CD34− Cells at the Apex of the Human Hematopoietic Stem Cell Hierarchy Have Distinctive Cellular and Molecular Signatures. Cell stem cell, Vol.13 (2), pp. 161-174.

Davies, J.K. Taussig, D. Oakervee, H. Smith, M. Agrawal, S. Cavenagh, J.D. Gribben, J.G. (2013). Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion. British journal of haematology, Vol.162 (4), pp. 525-529.

Rouault-Pierre, K. Lopez-Onieva, L. Foster, K. Anjos-Afonso, F. Lamrissi-Garcia, I. Serrano-Sanchez, M. Mitter, R. Ivanovic, Z. de Verneuil, H. Gribben, J. Taussig, D. Rezvani, H.R. Mazurier, F. Bonnet, D. (2013). HIF-2α Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress. Cell stem cell, Vol.13 (5), pp. 549-563.

Miraki-Moud, F. Anjos-Afonso, F. Hodby, K.A. Griessinger, E. Rosignoli, G. Lillington, D. Jia, L. Davies, J.K. Cavenagh, J. Smith, M. Oakervee, H. Agrawal, S. Gribben, J.G. Bonnet, D. Taussig, D.C. (2013). Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proceedings of the national academy of sciences, Vol.110 (33), pp. 13576-13581. show abstract

Vargaftig, J. Taussig, D.C. Griessinger, E. Anjos-Afonso, F. Lister, T.A. Cavenagh, J. Oakervee, H. Gribben, J. Bonnet, D. (2012). Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. Leukemia, Vol.26 (4), pp. 858-860.

Joshi, N.M. Hassan, S. Jasani, P. Dixon, S. Cavenagh, J.D. Oakervee, H.E. Smith, M. Agrawal, S.A. Auer, R. de Vos, J. Langmead, L. Rampton, D.S. Gribben, J.G. Taussig, D.C. (2012). Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract. British journal of haematology, Vol.157 (3), pp. 403-407.

Auer, R.L. MacDougall, F. Oakervee, H.E. Taussig, D. Davies, J.K. Syndercombe-Court, D. Agrawal, S. Cavenagh, J.D. Lister, T.A. Gribben, J.G. (2012). T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. British journal of haematology, Vol.157 (5), pp. 580-585.

Szlosarek, P.W. Luong, F. Clear, A. Taussig, D. Joel, S. Calaminici, M. Debernardi, S. Fitzgibbon, J. Bomalaski, J.S. Frankel, A.E. Bonnet, D. (2011). Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia. Cancer research, Vol.71.

Farren, T.W. Giustiniani, J. Liu, F.-. Tsitsikas, D.A. Macey, M.G. Cavenagh, J.D. Oakervee, H.E. Taussig, D. Newland, A.C. Calaminici, M. Bensussan, A. Jenner, M. Gribben, J.G. Agrawal, S.G. (2011). Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood, Vol.118 (8), pp. 2174-2183. show abstract

Taussig, D.C. Vargaftig, J. Miraki-Moud, F. Griessinger, E. Sharrock, K. Luke, T. Lillington, D. Oakervee, H. Cavenagh, J. Agrawal, S.G. Lister, T.A. Gribben, J.G. Bonnet, D. (2010). Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction. Blood, Vol.115 (10), pp. 1976-1984. show abstract

Le Dieu, R. Taussig, D. Lister, T.A. Gribben, J.G. (2009). Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. Journal of immunological methods, Vol.348 (1-2), pp. 95-100.

Anjos-Afonso, F. Taussig, D. Bonnet, D. (2009). PERTURBED BONE MARROW MESENCHYMAL STROMAL (MSC) COMPARTMENT IN AML PATIENTS: IMPLICATION FOR UNDERSTANDING LEUKEMIC MICROENVIRONMENT. Experimental hematology, Vol.37 (9), pp. S52-S53.

Le Dieu, R. Taussig, D.C. Ramsay, A.G. Mitter, R. Miraki-Moud, F. Fatah, R. Lee, A.M. Lister, T.A. Gribben, J.G. (2009). Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood, Vol.114 (18), pp. 3909-3916. show abstract

Taussig, D.C. Miraki-Moud, F. Anjos-Afonso, F. Pearce, D.J. Allen, K. Ridler, C. Lillington, D. Oakervee, H. Cavenagh, J. Agrawal, S.G. Lister, T.A. Gribben, J.G. Bonnet, D. (2008). Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood, Vol.112 (3), pp. 568-575. show abstract

Le Dieu, R. Ramsay, A.G. Taussig, D. Mitter, R. Gribben, J.G. (2008). Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis. Blood, Vol.112 (11), pp. 433-433.

Pearce, D.J. Taussig, D. Zibara, K. Smith, L.-. Ridler, C.M. Preudhomme, C. Young, B.D. Rohatiner, A.Z. Lister, T.A. Bonnet, D. (2006). AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood, Vol.107 (3), pp. 1166-1173. show abstract

Pearce, D. Taussig, D. Bonnet, D. (2006). Implications of the Expression of Myeloid Markers on Normal and Leukemic Stem Cells. Cell cycle, Vol.5 (3), pp. 271-273.

Davies, J.K. Taussig, D.C. Oakervee, H. Davies, A.J. Agrawal, S.G. Gribben, J.G. Lister, T.A. Cavenagh, J.D. (2006). Long-Term Follow-Up After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome: Late CNS Relapses Despite Graft-Versus-Host Disease. Journal of clinical oncology, Vol.24 (14), pp. e23-e25.

Pearce, D.J. Taussig, D. Simpson, C. Allen, K. Rohatiner, A.Z. Lister, T.A. Bonnet, D. (2005). Characterization of Cells with a High Aldehyde Dehydrogenase Activity from Cord Blood and Acute Myeloid Leukemia Samples. Stem cells, Vol.23 (6), pp. 752-760.

Taussig, D.C. (2005). Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood, Vol.106 (13), pp. 4086-4092.

TAUSSIG, D. (2003). Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J clin oncol, Vol.21, pp. 3060-3065.

Allen, D. (2002). Sternal osteomyelitis caused by Aspergillus fumigatus in a patient with previously treated Hodgkin's disease. Journal of clinical pathology, Vol.55 (8), pp. 616-618.

Longhurst, H.J. Taussig, D. Haque, T. Court, D.S. Cavenagh, J. Edgar, J.D. Helbert, M.R. (2002). Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndrome. British journal of haematology, Vol.116 (2), pp. 497-499.

(2002). Male Cells in Female Recipients of Hematopoietic-Cell Transplants. New england journal of medicine, Vol.347 (3), pp. 218-220.

Taussig, D.C. Pearce, D.J. Bonnet, D.A. (2002). Male cells in female recipients of hematopoietic-cell transplants. New england journal of medicine, Vol.347 (3), pp. 219-219.

Foran, J.M. Norton, A.J. Micallef, I.N. Taussig, D.C. Amess, J.A. Rohatiner, A.Z. Lister, T.A. (2001). Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. British journal of haematology, Vol.114 (4), pp. 881-883.

Taussig, D. Williams, M.A. Wiggins, C. Feakins, R.M. McBride, N. Newland, A.C. Kelsey, S.M. (1998). Clinical Regression and Remission of Primary Refractory Angiocentric Lymphoma Following Autologous Tumour Peptide Antigen-charged Dendritic Cells After High-dose Chemotherapy and Autologous Stem Cell Rescue. Hematology, Vol.3 (4), pp. 277-289.

(1997). Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac Surgery. New england journal of medicine, Vol.336 (20), pp. 1452-1454.

Konopleva, M.Y. Röllig, C. Cavenagh, J. Deeren, D. Girshova, L. Krauter, J. Martinelli, G. Montesinos, P. Schäfer, J.A. Ottmann, O.G. Petrini, M. Pigneux, A. Rambaldi, A. Recher, C. Rodriguez-Veiga, R. Taussig, D. Vey, N. Yoon, S.-. Ott, M.G. Muehlbauer, S. Beckermann, B.M. Catalani, O. Genevray, M. Mundt, K.E. Jamois, C. Fenaux, P. Wei, A.H. Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. Blood advances, . show abstract

Marks, D.I. Kirkwood, A.A. Rowntree, C.J. Aguiar, M. Bailey, K.E. Beaton, B. Cahalin, P. Castleton, A.Z. Clifton-Hadley, L. Copland, M. Goldstone, A.H. Kelly, R. Lawrie, E. Lee, S. McMillan, A.K. McMullin, M.F. Menne, T.F. Mitchell, R.J. Moorman, A.V. Patel, B. Patrick, P. Smith, P. Taussig, D. Yallop, D. Alapi, K.Z. Fielding, A.K. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. The lancet. haematology, Vol.9 (4), pp. e262-e275. show abstract

Background

Treatment for adults with acute lymphoblastic leukaemia requires improvement. UKALL14 was a UK National Cancer Research Institute Adult ALL group study that aimed to determine the benefit of adding the anti-CD20 monoclonal antibody, rituximab, to the therapy of adults with de novo B-precursor acute lymphoblastic leukaemia.

Methods

This was an investigator-initiated, phase 3, randomised controlled trial done in all UK National Health Service Centres treating patients with acute lymphoblastic leukaemia (65 centres). Patients were aged 25-65 years with de-novo BCR-ABL1-negative acute lymphoblastic leukaemia. Patients with de-novo BCR-ABL1-positive acute lymphoblastic leukaemia were eligible if they were aged 19-65 years. Participants were randomly assigned (1:1) to standard-of-care induction therapy or standard-of-care induction therapy plus four doses of intravenous rituximab (375 mg/m² on days 3, 10, 17, and 24). Randomisation used minimisation and was stratified by sex, age, and white blood cell count. No masking was used for patients, clinicians, or staff (including the trial statistician), although the central laboratory analysing minimal residual disease and CD20 was masked to treatment allocation. The primary endpoint was event-free survival in the intention-to-treat population. Safety was assessed in all participants who started trial treatment. This study is registered with ClincialTrials.gov, NCT01085617.

Findings

Between April 19, 2012, and July 10, 2017, 586 patients were randomly assigned to standard of care (n=292) or standard of care plus rituximab (n=294). Nine patients were excluded from the final analysis due to misdiagnosis (standard of care n=4, standard of care plus rituximab n=5). In the standard-of-care group, median age was 45 years (IQR 22-65), 159 (55%) of 292 participants were male, 128 (44%) were female, one (<1%) was intersex, and 143 (59%) of 244 participants had high-risk cytogenetics. In the standard-of-care plus rituximab group, median age was 46 years (IQR 23-65), 159 (55%) of 294 participants were male, 130 (45%) were female, and 140 (60%) of 235 participants had high-risk cytogenetics. After a median follow-up of 53·7 months (IQR 40·3-70·4), 3-year event-free survival was 43·7% (95% CI 37·8-49·5) for standard of care versus 51·4% (45·4-57·1) for standard of care plus rituximab (hazard ratio [HR] 0·85 [95% CI 0·69-1·06]; p=0·14). The most common adverse events were infections and cytopenias, with no difference between the groups in the rates of adverse events. There were 11 (4%) fatal (grade 5) events in induction phases 1 and 2 in the standard-of-care group and 13 (5%) events in the standard-of-care plus rituximab group). 3-year non-relapse mortality was 23·7% (95% CI 19·0-29·4) in the standard-of-care group versus 20·6% (16·2-25·9) in the standard-of-care plus rituximab group (HR 0·88 [95% CI 0·62-1·26]; p=0·49).

Interpretation

Standard of care plus four doses of rituximab did not significantly improve event-free survival over standard of care. Rituximab is beneficial in acute lymphoblastic leukaemia but four doses during induction is likely to be insufficient.

Funding

Cancer Research UK and Blood Cancer UK..

Waclawiczek, A. Hamilton, A. Rouault-Pierre, K. Abarrategi, A. Albornoz, M.G. Miraki-Moud, F. Bah, N. Gribben, J. Fitzgibbon, J. Taussig, D. Bonnet, D. Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. The journal of clinical investigation, Vol.130 (6), pp. 3038-3050. show abstract

Tiong, I.S. Dillon, R. Ivey, A. Teh, T.-. Nguyen, P. Cummings, N. Taussig, D.C. Latif, A.-. Potter, N.E. Runglall, M. Russell, N.H. Raj, K. Schwarer, A.P. Fong, C.Y. Grigg, A.P. Wei, A.H. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. British journal of haematology, Vol.192 (6), pp. 1026-1030. show abstract

Conferences

Hassan, S.Davies, J.Smith, M.Tsitsikas, D.Oakervee, H.Hallam, S.Taussig, D.Gribben, J.Cavenagh, J. (2015). DURABLE REMISSIONS AFTER SEQUENTIAL TRANSPLANTATION USING T-REPLETE NON-MYELOABLATIVE CONDITIONING FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA, HAEMATOLOGICA, Vol.100, p.278.

Hassan, S.Matthews, J.Guy, A.Farrell, M.Taussig, D.Smith, M.Oakervee, H.Cavenagh, J.Gribben, J. (2014). REDUCED INTENSITY ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA, BONE MARROW TRANSPLANTATION, Vol.49, pp.S350-S351.

Manodoro, F.Marzec, J.Chaplin, T.Miraki-Moud, F.Moravcsik, E.Jovanovic, J.V.Wang, J.Iqbal, S.Taussig, D.Grimwade, D.Gribben, J.G.Young, B.D.Debernardi, S. (2014). Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukaemia, BRITISH JOURNAL OF HAEMATOLOGY, Vol.165, p.16.

Ghazaly, E.Smith, P.Gnanaranjan, C.Young, B.D.Joel, S.Gribben, J.G.Taussig, D.C. (2014). SKIP Is Underexpressed in AML Leading to Sphingosine Kinase Hypofunction, BLOOD, Vol.124 (21).

Miraki-Moud, F.Ariza-McNaughton, L.Ghazaly, E.A.Hodby, K.A.Luong, P.Clear, A.Sohrabi, F.Bomalaski, J.Gribben, J.Bonnet, D.Szlosarek, P.Taussig, D.C. (2013). Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo, Blood, Vol.122 (21), p.1458.

Jasani, P.D.MacDougall, F.Smith, M.L.Cavenagh, J.D.Lister, T.A.Gribben, J.G.Taussig, D.C.Oakervee, H.E. (2012). Treatment of acute myeloid leukaemia in the elderly: a retrospective analysis, BRITISH JOURNAL OF HAEMATOLOGY, Vol.157, pp.64-65.

Iyengar, S.Ariza-McNaughton, L.Clear, A.J.Roe, A.Lillington, D.Taussig, D.C.Gribben, J.G.Joel, S.Bonnet, D. (2012). Human Primary Mantle Cell Lymphoma Can Be Established in NOD/SCID/IL2Rγ-Null Mice, Blood, Vol.120 (21), p.1565.

Butler, T.Montoya, A.Clear, A.J.Coutinho, R.Taussig, D.C.Cutillas, P.Gribben, J.G. (2012). Anergic Response to B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: The Differing Roles of IgD and IgM in the Microenvironment and Peripheral Blood., Blood, Vol.120 (21), p.2889.

Butler, T.Taussig, D.Cutillas, P.Gribben, J. (2012). PHOSPHOPROTEOMIC ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND B-CELL RECEPTOR SIGNALING SUGGESTS NOVEL THERAPEUTIC TARGETS, HAEMATOLOGICA, Vol.97, p.49.

Greaves, P.Iqbal, S.Rosignoli, G.Matthews, J.Wilson, A.Taussig, D.Gribben, J. (2012). DOMINANCE OF NAIVE AND CENTRAL MEMORY CD4+T CELLS IN THE CLASSICAL HODGKIN LYMPHOMA MICROENVIRONMENT PROVIDES A DISTINCTIVE SIGNATURE WITH IMPLICATIONS FOR PATHOGENESIS AND CLINICAL DIAGNOSIS, HAEMATOLOGICA, Vol.97, p.81.

Szlosarek, P.W.Luong, F.Clear, A.Taussig, D.Joel, S.Calaminici, M.Debernardi, S.Fitzgibbon, J.Bomalaski, J.S.Frankel, A.E.Bonnet, D. (2011). Abstract 4067: Pegylated arginine deiminase (ADI-PEG20) as a potential novel therapy for argininosuccinate synthetase-deficient acute myeloid leukemia, Presented at Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL, Cellular and Molecular Biology, .

Taussig, D.C.Gribben, J.G. (2011). Continuous CD4+ T Cell Lines Derived From the Classical Hodgkin Lymphoma Microenvironment: A Challenge to the Assumption of Anergy, BLOOD, Vol.118 (21), pp.1556-1557.

Mannari, D.Jasani, P.MacDougall, F.Taussig, D.Cavenagh, J. (2010). ALLOGENEIC HAEMOPOIETIC STEM-CELL TRANSPLANTATION USING A NON T-CELL DEPLETE REDUCED INTENSITY CONDITIONING PROTOCOL FOR ACUTE MYELOID LEUKAEMIA & MYELODYSPLASIA: A 10-YEAR SINGLE CENTRE EXPERIENCE, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.95, p.275.

Ghazaly, E.Smith, P.Quentmeier, H.Drexler, H.Iqbal, S.Taussig, D.Young, B.Lister, A.Joel, S.Fitzgibbon, J. (2010). ACCUMULATION OF 2-HYDROXYGLUTARATE (2-HG) IN NORMAL KARYOTYPE AML PATIENTS WITH IDH1 MUTATION, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.95, p.20.

Taussig, D.Miraki-Moud, F.Lister, A.Bonnet, D.Gribben, J. (2010). BONE MARROW FAILURE IN ACUTE MYELOID LEUKEMIA IS INDUCED BY A BLOCK IN DIFFERENTIATION OF NORMAL HEMATOPOIETIC STEM CELLS, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol.95, p.13.

Mannari, D.Jasani, P.Macdougall, F.Taussig, D.Cavenagh, J. (2010). ALLOGENEIC HAEMOPOIETIC STEM-CELL TRANSPLANTATION USING A NON T-CELL DEPLETE REDUCED INTENSITY CONDITIONING PROTOCOL FOR ACUTE MYELOID LEUKAEMIA & MYELODYSPLASIA: A 10-YEAR SINGLE CENTRE EXPERIENCE, HAEMATOLOGICA, Vol.95, p.275.

Tsitsikas, D.A.Warcel-Sibony, D.Oakervee, H.E.Agrawal, S.G.Smith, M.Taussig, D.C.de Vos, J.Stewart, E.Nicholas, H.Gribben, J.G.Cavenagh, J.D. (2010). A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report, BLOOD, Vol.116 (21), p.1430.

Le Dieu, R.Taussig, D.MacDougal, F.Lister, A.Gribben, J.G. (2007). CD3+/CD56+cells, but not natural killer T cells, are increased in peripheral blood of untreated patients with leukemia, BLOOD, Vol.110 (11), p.538A.

Pearce, D.J.Taussig, D.Eddaoudi, A.Bonnet, D. (2005). Age-dependent changes in hematopoietic stem and progenitor cells, EXPERIMENTAL HEMATOLOGY, Vol.33 (7), p.90.

Zibara, K.Pearce, D.Taussig, D.Bureau, E.Skoulakis, S.Tomlinson, S.Young, B. (2005). Gene expression profiling reveals fundamental differences between leukemic stem cells (Lin-CD34+CD38-) and mature blasts (Lin-CD34+CD38+) of acute myeloid leukaemia (AML) patients, EXPERIMENTAL HEMATOLOGY, Vol.33 (7), p.83.

Zibara, K.Pearce, D.Taussig, D.Skoulakis, S.Tomlinson, S.Bureau, E.Young, B.D.Bonnet, D. (2005). Gene expression profiling reveals fundamental differences between leukemic stem cells (Lin-CD34+CD38-) and mature blasts (Lin-CD34+CD38+) of acute myeloid leukaemia (AML) patients., BLOOD, Vol.106 (11), p.399A.

Pearce, D.J.Taussig, D.Simpson, C.Bonnet, D. (2004). A high ALDH activity identifies both normal and leukemic stem cells, BLOOD, Vol.104 (11), p.199B.

Taussig, D.Pearce, D.J.Simpson, C.Rohatiner, A.Lister, T.A.Bonnet, D. (2003). Acute myeloid leukaemia stem cells express the CD33 antigen., BLOOD, Vol.102 (11), p.143B.

Oakervee, H.E.Gordon, A.C.Kaya, B.Taussig, D.C.Lockley, M.Barnett, M.J.Rohatiner, A.Z.Lister, T.A.Hinds, C.J.Cavenagh, J.D. (2002). Outcomes of critical illness in patients with haematological malignancy., BLOOD, Vol.100 (11), pp.875A-876A.

Taussig, D.C.Cavenagh, J.D.Davies, A.J.Oakervee, H.Syndercombe-Court, D.Kelsey, S.M.Barnett, M.J.Rohatiner, A.Lister, A. (2002). Non-myeloablative allografting for patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML)., BLOOD, Vol.100 (11), pp.409A-410A.

Taussig, D.C.Davies, C.Taha, Y.Protheroe, R.Oakervee, H.Davies, A.J.Rohatiner, A.Aitken, C.Cavenagh, J.D.Lister, A. (2002). Early identification of respiratory virus infection in inpatients with haematological malignancies reduces nosocomial spread., BLOOD, Vol.100 (11), p.436B.

Pearce, D.Taussig, D.Rohatiner, A.Bonnet, D. (2002). Comparison of AML engraftment in murine NOD/SCID and beta 2m-/-, NOD/SCID xenotransplantation assays., BLOOD, Vol.100 (11), p.555A.

Davies, A.J.Micallef, I.N.Taussig, D.C.Cavenagh, J.D.Foran, J.M.McBride, N.Syndercombe-Court, D.Kelsey, S.M.Lister, T.A.Rohatiner, A.Z. (2000). An open phase II study of non-myeloablative allogeneic stem cell transplantation for refractory/recurrent and poor risk haematological malignancy., BLOOD, Vol.96 (11), p.353B.

Williams, M.A.Taussig, D.C.Wiggins, C.Feakins, R.M.McBride, N.Newland, A.C.Kelsey, S.M. (1998). Clinical remission of primary refractory lymphoma following infusion of autologous tumour-peptide charged dendritic cells after myeloablative chemotherapy., JOURNAL OF LEUKOCYTE BIOLOGY, , p.101.